Emmaus Life Sciences, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details Narrative)

CONVERTIBLE DEBT AND EQUITY FINANCINGS (Details Narrative)								1 Months Ended	12 Months Ended
	Aug. 24, 2017 USD ($) $ / shares shares	Jul. 19, 2017 USD ($) $ / shares shares	Jul. 13, 2017 USD ($) $ / shares shares	Sep. 21, 2016 USD ($) $ / shares shares	Sep. 19, 2016 USD ($) $ / shares shares	Dec. 23, 2015 USD ($) Investor $ / shares shares	Apr. 14, 2015 USD ($)	Jul. 31, 2017 USD ($) $ / shares shares	Sep. 30, 2017 USD ($) Investor shares	Sep. 30, 2016 USD ($) shares	Sep. 16, 2016 Investor	Sep. 30, 2015 USD ($)	Sep. 24, 2015 USD ($) Investor	Sep. 14, 2015 $ / shares	Sep. 22, 2014 USD ($)
Purchase of convertible note										$ 6,000,000		$ 3,000,000
Accrued Interest										$ 317,000
Shares issued on Conversion \| shares										1,263,406
Proceeds from public offering									$ 7,482,100
Public Offering [Member]
Proceeds from public offering								$ 8,793,750
Stock price (in dollars per share) \| $ / shares								$ 5.25
Offering cost associated with underwriters								$ 1,313,800
45-day Option Over-Allotment Option [Member]
Number of common stock issued \| shares								251,250
Warrant [Member] \| Public Offering [Member]
Maturity date of the notes		Jul. 19, 2022						Jul. 19, 2022
Number of common stock issued \| shares		134,000						1,675,000
Warrant exercise price (in dollars per share) \| $ / shares		$ 6.04						$ 5.25
Number of each warrant called \| shares								1
Stock price (in dollars per share) \| $ / shares		$ 6.55						$ 6.55
Warrant term								5 years
Fair value of the public offering		$ 863,225						$ 10,802,728
Fair value, maturity		5 years						5 years
Volatility rate		211.60%						211.60%
Expected dividend rate		0.00%						0.00%
Risk free interest rate		1.89%						1.89%
Warrant [Member] \| 45-day Option Over-Allotment Option [Member]
Maturity date of the notes	Jul. 19, 2022
Number of common stock issued \| shares	213,800
Warrant exercise price (in dollars per share) \| $ / shares	$ 5.25
Stock price (in dollars per share) \| $ / shares	$ 4.20
Warrant term	5 years
Fair value of the public offering	$ 880,710
Fair value, maturity	5 years
Volatility rate	211.60%
Expected dividend rate	0.00%
Risk free interest rate	1.89%
Proceeds from issuance of warrants	$ 2,100
Warrant [Member] \| Pro-Rate Option [Member]
Maturity date of the notes			Jul. 26, 2022
Number of common stock issued \| shares			2,539,061
Warrant exercise price (in dollars per share) \| $ / shares			$ 5.25
Number of each warrant called \| shares			1
Stock price (in dollars per share) \| $ / shares			$ 6.55
Warrant term			5 years
Fair value of the public offering			$ 16,375,394
Fair value, maturity			5 years
Volatility rate			211.60%
Expected dividend rate			0.00%
Risk free interest rate			1.89%
Common Stock [Member]
Number of common stock issued \| shares									26,250	1,500
Common Stock [Member] \| Public Offering [Member]
Number of common stock issued \| shares								1,675,000
Common Stock and Warrants [Member] \| Public Offering [Member]
Proceeds from public offering								$ 8,790,000
John Pappajohn [Member]
Number of accredited investors \| Investor											4
5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| John Pappajohn [Member]
Accrued Interest									$ 10,400
Shares issued on Conversion \| shares									42,084
Second Amended Note & Warrant Agreement [Member]
Face amount					$ 6,000,000
Conversion price (in dollars per share) \| $ / shares					$ 5.00
Accrued Interest					$ 317,000
Shares issued on Conversion \| shares					1,263,406
Second Amended Note & Warrant Agreement [Member] \| Note Warrant [Member]
Conversion price (in dollars per share) \| $ / shares						$ 50.00
Number of shares called \| shares						3,000,000
Second Amended Note & Warrant Agreement [Member] \| Sixteen Accredited Investors [Member]
Number of accredited investors \| Investor						16
Purchase of convertible note						$ 6,000,000
Maturity date of the notes						Dec. 31, 2017
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member]
Face amount						$ 1,000,000
Conversion price (in dollars per share) \| $ / shares						$ 5.00
Description of collateral						Secured by a security interest in the Company's intellectual property, as detailed in the amended and restated security agreement.
Description of repayment priority						Upon a change of control of the Company (as described in the Notes), the holder of a Note will have the option to have the Note repaid with a premium equal to 50% of the outstanding principal.
Accrued Interest						$ 317,000
Second Amended Note & Warrant Agreement [Member] \| Secured Convertible Promissory Notes ( December 2015 Notes) [Member] \| Warrant [Member]
Description of conversion terms						Each such holder was issued an Extension Warrant to purchase Common Stock in an amount equal to 100% of the shares underlying each such holder’s previously outstanding Notes.
Number of shares called \| shares						300,000
Amendment Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount							$ 3,000,000
Issuance of debt							$ 500,000
Conversion price (in dollars per share) \| $ / shares														$ 10.00
Description of conversion terms									Conversion price of all notes at $10.00 per share (as adjusted for stock splits, stock dividends, combinations or the like affecting the Common Stock) (the “Fixed Conversion Price”) (i) automatically, in the event of a qualified financing of not less than $5 million, or (ii) voluntarily, within 15 days prior to the maturity date of the note. The Omnibus Amendment also amended the form of note attached to the Note Purchase Agreement to reflect the Fixed Conversion Price.
Amendment Note Purchase Agreement [Member] \| Secured Convertible Promissory Notes (September 2015 Notes) [Member] \| Six Accredited Investors [Member]
Number of accredited investors \| Investor													6
Face amount													$ 710,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount															$ 2,500,000
Purchase of convertible note						$ 3,121,900						$ 3,000,000
Accrued Interest						$ 121,900
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity (Michal Votruba) [Member]
Purchase of convertible note									$ 750,000
Original Note Purchase Agreement [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member] \| RSJ Private Equity & Nine Accredited Investors [Member]
Number of accredited investors \| Investor									9
Number of secured notes issued \| Investor									15
Face amount									$ 2,290,000
Second Omnibus Amendment [Member]
Face amount					$ 6,000,000
Conversion price (in dollars per share) \| $ / shares				$ 5.00	$ 5.00
Accrued Interest				$ 317,000
Shares issued on Conversion \| shares				1,263,406
Second Omnibus Amendment [Member] \| 5% Senior Secured Notes Convertible (the "September 2014 Notes") [Member]
Face amount					$ 6,000,000
Conversion price (in dollars per share) \| $ / shares					$ 5.00
Number of shares called \| shares					1,263,406
Accrued Interest					$ 316,965
Warrant exercise price (in dollars per share) \| $ / shares					$ 0.05
Second Omnibus Amendment [Member] \| Secured Convertible Promissory Notes [Member]
Description of conversion terms					Pursuant to the Second Omnibus Amendment, the Company had the option, exercisable at any time after September 1, 2016, to mandatorily convert all Notes into shares of the Company's common stock at $5.00 per share (the "Mandatory Conversion").